詳細検索

詳細検索

お問い合わせ

Global Killed-type Poultry Vaccine Market Outlook, InDepth Analysis & Forecast to 2032

Global Killed-type Poultry Vaccine Market Outlook, InDepth Analysis & Forecast to 2032


家禽用死菌ワクチンの世界市場 2026-2032年

The global Killed-type Poultry Vaccine market is projected to grow from US$ 1455 million in 2025 to US$ 1987 million by 2032, at a CAGR of 4.6% (2026-2032), driven by critical product segments and ... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月16日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Killed-type Poultry Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Killed-type Poultry Vaccine Revenue, 2025
Table 13. Global Killed-type Poultry Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Killed-type Poultry Vaccine Companies Headquarters
Table 15. Global Killed-type Poultry Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 21. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 22. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2021-2026
Table 23. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Killed-type Poultry Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Killed-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 31. North America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Killed-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Killed-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Killed-type Poultry Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Killed-type Poultry Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Killed-type Poultry Vaccine SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Killed-type Poultry Vaccine SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Killed-type Poultry Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Killed-type Poultry Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Killed-type Poultry Vaccine SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. HIPRA Corporation Information
Table 86. HIPRA Description and Major Businesses
Table 87. HIPRA Product Features and Attributes
Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. HIPRA Recent Developments
Table 90. Vaxxinova Corporation Information
Table 91. Vaxxinova Description and Major Businesses
Table 92. Vaxxinova Product Features and Attributes
Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Vaxxinova Recent Developments
Table 95. QYH Biotech Corporation Information
Table 96. QYH Biotech Description and Major Businesses
Table 97. QYH Biotech Product Features and Attributes
Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. QYH Biotech Recent Developments
Table 100. Pulike Corporation Information
Table 101. Pulike Description and Major Businesses
Table 102. Pulike Product Features and Attributes
Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Pulike Recent Developments
Table 105. Harbin Pharmaceutical Group Corporation Information
Table 106. Harbin Pharmaceutical Group Description and Major Businesses
Table 107. Harbin Pharmaceutical Group Product Features and Attributes
Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Harbin Pharmaceutical Group Recent Developments
Table 110. Nisseiken Corporation Information
Table 111. Nisseiken Description and Major Businesses
Table 112. Nisseiken Product Features and Attributes
Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Nisseiken Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Globion India Corporation Information
Table 121. Globion India Description and Major Businesses
Table 122. Globion India Product Features and Attributes
Table 123. Globion India Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Globion India Recent Developments
Table 125. Venkys India Corporation Information
Table 126. Venkys India Description and Major Businesses
Table 127. Venkys India Product Features and Attributes
Table 128. Venkys India Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Venkys India Recent Developments
Table 130. Bioveta Corporation Information
Table 131. Bioveta Description and Major Businesses
Table 132. Bioveta Product Features and Attributes
Table 133. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Bioveta Recent Developments
Table 135. Jilin Zhengye Corporation Information
Table 136. Jilin Zhengye Description and Major Businesses
Table 137. Jilin Zhengye Product Features and Attributes
Table 138. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Jilin Zhengye Recent Developments
Table 140. Yebio Corporation Information
Table 141. Yebio Description and Major Businesses
Table 142. Yebio Product Features and Attributes
Table 143. Yebio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Yebio Recent Developments
Table 145. Sinder Corporation Information
Table 146. Sinder Description and Major Businesses
Table 147. Sinder Product Features and Attributes
Table 148. Sinder Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Sinder Recent Developments
Table 150. DHN Corporation Information
Table 151. DHN Description and Major Businesses
Table 152. DHN Product Features and Attributes
Table 153. DHN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. DHN Recent Developments
Table 155. JinYu Biotechnology Corporation Information
Table 156. JinYu Biotechnology Description and Major Businesses
Table 157. JinYu Biotechnology Product Features and Attributes
Table 158. JinYu Biotechnology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. JinYu Biotechnology Recent Developments
Table 160. Guangzhou South China Biological Medicine Corporation Information
Table 161. Guangzhou South China Biological Medicine Description and Major Businesses
Table 162. Guangzhou South China Biological Medicine Product Features and Attributes
Table 163. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Guangzhou South China Biological Medicine Recent Developments
Table 165. Technologies, Platforms and Infrastructure
Table 166. Distributors List
Table 167. Market Trends and Market Evolution
Table 168. Market Drivers and Opportunities
Table 169. Market Challenges, Risks, and Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Newcastle Disease Vaccines Product Picture
Figure 3. Infectious Bronchitis Vaccines Product Picture
Figure 4. Others Product Picture
Figure 5. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Monovalent Vaccines Product Picture
Figure 7. Multivalent / Combination Vaccines Product Picture
Figure 8. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million)
Figure 9. Preventive Vaccines Product Picture
Figure 10. Prime Vaccines Product Picture
Figure 11. Booster Vaccines Product Picture
Figure 12. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Broiler Farming
Figure 14. Layer Farming
Figure 15. Breeder Farming
Figure 16. Others
Figure 17. Killed-type Poultry Vaccine Report Years Considered
Figure 18. Global Killed-type Poultry Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 19. Global Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 20. Global Killed-type Poultry Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 22. Global Killed-type Poultry Vaccine Revenue-Based Market Share Ranking (2025)
Figure 23. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 24. Newcastle Disease Vaccines Revenue-Based Market Share by Player in 2025
Figure 25. Infectious Bronchitis Vaccines Revenue-Based Market Share by Player in 2025
Figure 26. Others Revenue-Based Market Share by Player in 2025
Figure 27. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 28. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 29. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Function (2021-2032)
Figure 30. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 31. North America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 32. North America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 33. North America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 34. US Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 35. Canada Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 36. Mexico Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 37. Europe Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 38. Europe Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 39. Europe Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 40. Germany Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 41. France Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 42. U.K. Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 43. Italy Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 44. Russia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 45. Asia-Pacific Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 46. Asia-Pacific Top 8 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 47. Asia-Pacific Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 48. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 49. Japan Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 50. South Korea Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 51. Australia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 52. India Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 53. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 54. Vietnam Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Malaysia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 56. Philippines Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Singapore Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Central and South America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 59. Central and South America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 60. Central and South America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 61. Brazil Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 62. Argentina Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 63. Middle East and Africa Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 64. Middle East and Africa Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 65. Middle East and Africa Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 66. GCC Countries Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 67. Israel Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 68. Egypt Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 69. South Africa Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 70. Killed-type Poultry Vaccine Value Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Killed-type Poultry Vaccine market is projected to grow from US$ 1455 million in 2025 to US$ 1987 million by 2032, at a CAGR of 4.6% (2026-2032), driven by critical product segments and diverse end‑use applications.

Killed-type Poultry Vaccines are veterinary biological products containing viral, bacterial, or other pathogen-derived antigens that have been propagated and then completely inactivated by methods such as formaldehyde or beta-propiolactone, eliminating replication capability while retaining immunogenicity. They are generally formulated with mineral oil, vegetable oil, or other adjuvants as injectable emulsions and are used for prevention, priming, or booster immunization in chickens and other poultry. By disease type, the product is classified into Newcastle Disease Vaccines, Infectious Bronchitis Vaccines, and Others; by Antigen Combination, into Monovalent Vaccines and Multivalent/Combination Vaccines; and by Function, into Preventive Vaccines, Prime Vaccines, and Booster Vaccines. Mainstream products use water-in-oil or related oil-emulsion systems and are administered intramuscularly or subcutaneously, typically at approximately 0.3–0.5 mL per bird. Potency is commonly evaluated using PD50, HI antibody titers, or VN antibody titers. Unlike live vaccines, these products do not replicate or spread vaccine virus after administration and are particularly suited to establishing durable humoral immunity in layers and breeders before the laying period.

Key Findings
The average industry gross margin in 2025 is approximately 45%–65%.

Newcastle Disease Vaccines represent the largest segment, with mainstream 0.5 mL-per-bird oil-emulsion products providing ≥50 PD50 or inducing ≥4.0 log2 HI at 1/50 dose.

Layer Farming represents the largest downstream application.

MSD Animal Health, Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health are positioned among the leading global suppliers.

Market Trends
The product is evolving from conventional monovalent oil emulsions toward multivalent combinations, higher antigen loading, reduced injection reactions, and longer-lasting immunity. Conventional monovalent Newcastle Disease products retain important baseline demand, but layers and breeders are increasingly vaccinated with combination products covering ND, IB, IBD, EDS, avian rhinotracheitis, or Salmonella in a single injection. MSD offers IB+ND, IB+G+ND, and RT+IB Multi+ND+EDS combinations, while Zoetis Maternavac 4 combines IBD, ND, Reovirus, and IB protection. Future technology development will focus on emulsion stability, reduced local tissue reactions, broader antigen combinations, and digital injection systems that improve dose and administration-site consistency.

Market Dynamics
Drivers
Demand for the product is primarily driven by the long production cycles of layers and breeders, the need to prevent declines in egg production, maintenance of flock antibody levels, and transfer of maternal antibodies to progeny. WOAH notes that inactivated Newcastle vaccines are commonly used as boosters following live priming before the onset of lay and can generate high and persistent serum antibody titers. Layer production cycles are substantially longer than broiler cycles, and ND, IB, or EDS infections after the onset of lay can directly affect egg output and quality, creating strong economic value for pre-lay injectable boosters. Breeder flocks additionally require high maternal antibody levels against diseases such as IBD and Reovirus to provide early passive protection to chicks.

Restraints
The largest restraint is the need for individual injection, which results in higher labor requirements and greater operational complexity than spray- or drinking-water-administered live vaccines. WOAH notes that inactivated vaccines are generally more expensive than live vaccines, require handling and injection of individual birds, and require greater antigen quantities because the antigen cannot replicate in the host. Oil emulsions may also cause local inflammation, nodules, or injection-site reactions, while incorrect administration can affect immunity and carcass quality. Products generally require refrigerated storage at 2–8°C and should not be frozen, as freezing or emulsion breakdown can impair stability. Their use also frequently depends on an appropriate live-vaccine priming program.

Opportunities
Future opportunities are concentrated in Multivalent/Combination Vaccines, long-duration protection for layers, maternal-antibody management in breeders, and precision injection systems. Combining multiple antigens reduces bird handling and injection frequency and therefore has substantial value for large layer and breeder operations. Boehringer Ingelheim's Gallimune 407 combines ND, IB, EDS, and avian rhinotracheitis antigens in one oil-emulsion product, while Zoetis Poulvac SE-ND-IB combines Salmonella, ND, and IB in one killed water-in-oil emulsion. Future portfolios can also incorporate regional IB variants, avian influenza subtypes, and bacterial pathogens, while automated injection and digital tracking systems can improve vaccination quality across large flocks.

Challenges
The core challenge is achieving complete inactivation while preserving sufficient antigenicity and maintaining long-term emulsion and batch stability. Inadequate inactivation creates a biosafety risk, while excessive chemical treatment may damage important antigenic epitopes and reduce potency. Newcastle Disease and Infectious Bronchitis viruses also have multiple strains and antigenic variants, and the degree of antigenic matching with field strains can influence protection. Multivalent products introduce additional challenges because different antigens may interact immunologically, requiring careful control of antigen ratios, adjuvant systems, and formulation consistency. As the number of antigens increases, manufacturers must simultaneously manage viscosity, injection convenience, local reactions, and duration of antibody response.

Industry Chain Analysis
The upstream supply chain mainly includes SPF embryonated eggs, avian or other cell-culture substrates, master and working seed viruses, culture media, inactivating agents, mineral- or vegetable-oil adjuvants, emulsifiers, sterile vials and packaging, as well as bioreactors, filling equipment, and cold-chain infrastructure. Midstream production includes pathogen propagation, antigen harvest, concentration and purification, inactivation, validation of complete inactivation, antigen quantification, oil-water emulsification, aseptic filling, potency testing, safety testing, and stability control. WOAH notes that inactivated Newcastle vaccine antigen may be obtained from allantoic fluid, inactivated with formaldehyde or beta-propiolactone, and incorporated into mineral- or vegetable-oil emulsions. Downstream demand comes from Broiler Farming, Layer Farming, Breeder Farming, and Other poultry operations through veterinary distributors, integrated poultry companies, and veterinary service networks, together with injectors, serological monitoring, and refrigerated logistics.

Segment Insights
By disease type, Newcastle Disease Vaccines represent the core segment. Nobilis Newcavac is a representative monovalent product based on inactivated Clone 30 antigen, administered at 0.5 mL per bird and containing at least 50 PD50 or inducing ≥4.0 log2 HI at 1/50 dose. Infectious Bronchitis Vaccines commonly use Massachusetts antigens such as M41 and are frequently combined with ND. Other categories include IBD, EDS, Reovirus, avian rhinotracheitis, Salmonella, and avian influenza.

By Antigen Combination and Function, Multivalent/Combination Vaccines represent the major high-value direction. Products can integrate three, four, or more antigens in one dose; RT+IB Multi+ND+EDS, for example, uses a 0.5 mL dose containing avian rhinotracheitis, two IB antigens, ND, and EDS antigens. Although the product can be used for preventive and prime immunization, its most characteristic function is as a Booster Vaccine. Nobilis Newcavac is intended for live-primed layers and breeders and is normally administered at least four weeks before the expected onset of lay, supporting a standardized “live prime + multivalent inactivated booster” strategy.

Downstream Market Opportunities
Layer Farming represents the largest application because the long production cycle and economic importance of egg output require durable humoral protection against ND, IB, EDS, and related diseases before the onset of lay. Breeder Farming is another important high-value application because protection of the parent flock must be combined with high maternal-antibody transfer against diseases such as IBD and Reovirus. Zoetis Maternavac 4 is intended for chickens 16–22 weeks of age and combines IBD, ND, Reovirus, and IB antigens to support breeder and progeny protection. Broiler Farming uses the product more selectively because of shorter production cycles and the cost of individual injection, although demand remains in high-disease-pressure, slow-growing broiler, and selected ND or avian-influenza programs. Artificial intelligence is not part of the vaccine itself, but it can analyze antibody titers, egg-production curves, mortality, and outbreak data to optimize booster timing and use vision systems to monitor injection accuracy and missed birds.

Regional Insights
Asia-Pacific is an important production and consumption region because of its large layer, breeder, and broiler industries and continued demand for control of ND, IB, avian influenza, and other diseases. Chinese participants include QYH Biotech, Pulike, Harbin Pharmaceutical Group, Jilin Zhengye, Shandong Huahong Biological Engineering, Yebio, Sinder, DHN, JinYu Biotechnology, and Guangzhou South China Biological Medicine, while India includes Hester Biosciences, Globion India, and Venky's India. Europe has established suppliers such as Boehringer Ingelheim, Ceva, HIPRA, Vaxxinova, and Bioveta and strong expertise in multivalent oil-emulsion vaccines; HIPRA offers monovalent ND, ND+IB, and four-way inactivated injectable emulsions. North America places strong emphasis on Salmonella control, breeder vaccination, and multivalent killed products, with Zoetis and Elanco maintaining broad inactivated portfolios.

Competitive Landscape Analysis
The product market has substantial barriers in seed-strain resources, SPF production, inactivation validation, oil-emulsion technology, cold-chain management, and regulatory approval. Representative leading players include MSD Animal Health (Merck), Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health. MSD's Nobilis portfolio extends from monovalent Newcavac to IB+ND, IB+G+ND, and RT+IB Multi+ND+EDS combinations; Zoetis uses Poulvac SE-ND-IB and Maternavac products to cover Salmonella, ND, IB, IBD, and Reovirus; Boehringer Ingelheim competes through Gallimune and Volvac multivalent oil-emulsion platforms; and Elanco's AviPro portfolio includes combinations targeting ND, IB, IBD, and Reovirus. Competition is shifting from basic antigen potency toward broader antigen combinations, duration of immunity, lower injection reactions, maternal-antibody management, and complete vaccination-program services.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Killed-type Poultry Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
MSD Animal Health(Merck)
Zoetis
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
HIPRA
Vaxxinova
QYH Biotech
Pulike
Harbin Pharmaceutical Group
Nisseiken
Hester Biosciences
Globion India
Venkys India
Bioveta
Jilin Zhengye
Yebio
Sinder
DHN
JinYu Biotechnology
Guangzhou South China Biological Medicine

Segment by Type
Newcastle Disease Vaccines
Infectious Bronchitis Vaccines
Others

Segment by Antigen Combination
Monovalent Vaccines
Multivalent / Combination Vaccines

Segment by Function
Preventive Vaccines
Prime Vaccines
Booster Vaccines

Segment by Application
Broiler Farming
Layer Farming
Breeder Farming
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Killed-type Poultry Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Killed-type Poultry Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Killed-type Poultry Vaccine Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Newcastle Disease Vaccines
1.2.3 Infectious Bronchitis Vaccines
1.2.4 Others
1.3 Market Segmentation by Antigen Combination
1.3.1 Global Killed-type Poultry Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032
1.3.2 Monovalent Vaccines
1.3.3 Multivalent / Combination Vaccines
1.4 Market Segmentation by Function
1.4.1 Global Killed-type Poultry Vaccine Market Size by Function, 2021 vs 2025 vs 2032
1.4.2 Preventive Vaccines
1.4.3 Prime Vaccines
1.4.4 Booster Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Killed-type Poultry Vaccine Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Broiler Farming
1.5.3 Layer Farming
1.5.4 Breeder Farming
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Killed-type Poultry Vaccine Revenue Estimates and Forecasts (2021-2032)
2.2 Global Killed-type Poultry Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Killed-type Poultry Vaccine Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Killed-type Poultry Vaccine Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Newcastle Disease Vaccines: Market Share by Key Players
3.3.2 Infectious Bronchitis Vaccines: Market Share by Key Players
3.3.3 Others: Market Share by Key Players
3.4 Global Killed-type Poultry Vaccine Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Killed-type Poultry Vaccine Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Killed-type Poultry Vaccine Market by Antigen Combination
4.2.1 Global Revenue by Antigen Combination (2021-2032)
4.2.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032)
4.3 Global Killed-type Poultry Vaccine Market by Function
4.3.1 Global Revenue by Function (2021-2032)
4.3.2 Global Revenue-Based Market Share by Function (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Killed-type Poultry Vaccine Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Killed-type Poultry Vaccine Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Killed-type Poultry Vaccine Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Killed-type Poultry Vaccine Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Killed-type Poultry Vaccine Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Killed-type Poultry Vaccine Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Killed-type Poultry Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Killed-type Poultry Vaccine Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Killed-type Poultry Vaccine Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Killed-type Poultry Vaccine Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Killed-type Poultry Vaccine Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 MSD Animal Health(Merck)
11.1.1 MSD Animal Health(Merck) Corporation Information
11.1.2 MSD Animal Health(Merck) Business Overview
11.1.3 MSD Animal Health(Merck) Killed-type Poultry Vaccine Product Features and Attributes
11.1.4 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.1.5 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue by Product in 2025
11.1.6 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue by Application in 2025
11.1.7 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue by Geographic Area in 2025
11.1.8 MSD Animal Health(Merck) Killed-type Poultry Vaccine SWOT Analysis
11.1.9 MSD Animal Health(Merck) Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Killed-type Poultry Vaccine Product Features and Attributes
11.2.4 Zoetis Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Killed-type Poultry Vaccine Revenue by Product in 2025
11.2.6 Zoetis Killed-type Poultry Vaccine Revenue by Application in 2025
11.2.7 Zoetis Killed-type Poultry Vaccine Revenue by Geographic Area in 2025
11.2.8 Zoetis Killed-type Poultry Vaccine SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Killed-type Poultry Vaccine Product Features and Attributes
11.3.4 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue by Product in 2025
11.3.6 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue by Application in 2025
11.3.7 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Killed-type Poultry Vaccine SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Business Overview
11.4.3 Ceva Santé Animale Killed-type Poultry Vaccine Product Features and Attributes
11.4.4 Ceva Santé Animale Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Santé Animale Killed-type Poultry Vaccine Revenue by Product in 2025
11.4.6 Ceva Santé Animale Killed-type Poultry Vaccine Revenue by Application in 2025
11.4.7 Ceva Santé Animale Killed-type Poultry Vaccine Revenue by Geographic Area in 2025
11.4.8 Ceva Santé Animale Killed-type Poultry Vaccine SWOT Analysis
11.4.9 Ceva Santé Animale Recent Developments
11.5 Elanco Animal Health
11.5.1 Elanco Animal Health Corporation Information
11.5.2 Elanco Animal Health Business Overview
11.5.3 Elanco Animal Health Killed-type Poultry Vaccine Product Features and Attributes
11.5.4 Elanco Animal Health Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.5.5 Elanco Animal Health Killed-type Poultry Vaccine Revenue by Product in 2025
11.5.6 Elanco Animal Health Killed-type Poultry Vaccine Revenue by Application in 2025
11.5.7 Elanco Animal Health Killed-type Poultry Vaccine Revenue by Geographic Area in 2025
11.5.8 Elanco Animal Health Killed-type Poultry Vaccine SWOT Analysis
11.5.9 Elanco Animal Health Recent Developments
11.6 HIPRA
11.6.1 HIPRA Corporation Information
11.6.2 HIPRA Business Overview
11.6.3 HIPRA Killed-type Poultry Vaccine Product Features and Attributes
11.6.4 HIPRA Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.6.5 HIPRA Recent Developments
11.7 Vaxxinova
11.7.1 Vaxxinova Corporation Information
11.7.2 Vaxxinova Business Overview
11.7.3 Vaxxinova Killed-type Poultry Vaccine Product Features and Attributes
11.7.4 Vaxxinova Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.7.5 Vaxxinova Recent Developments
11.8 QYH Biotech
11.8.1 QYH Biotech Corporation Information
11.8.2 QYH Biotech Business Overview
11.8.3 QYH Biotech Killed-type Poultry Vaccine Product Features and Attributes
11.8.4 QYH Biotech Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.8.5 QYH Biotech Recent Developments
11.9 Pulike
11.9.1 Pulike Corporation Information
11.9.2 Pulike Business Overview
11.9.3 Pulike Killed-type Poultry Vaccine Product Features and Attributes
11.9.4 Pulike Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.9.5 Pulike Recent Developments
11.10 Harbin Pharmaceutical Group
11.10.1 Harbin Pharmaceutical Group Corporation Information
11.10.2 Harbin Pharmaceutical Group Business Overview
11.10.3 Harbin Pharmaceutical Group Killed-type Poultry Vaccine Product Features and Attributes
11.10.4 Harbin Pharmaceutical Group Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Nisseiken
11.11.1 Nisseiken Corporation Information
11.11.2 Nisseiken Business Overview
11.11.3 Nisseiken Killed-type Poultry Vaccine Product Features and Attributes
11.11.4 Nisseiken Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.11.5 Nisseiken Recent Developments
11.12 Hester Biosciences
11.12.1 Hester Biosciences Corporation Information
11.12.2 Hester Biosciences Business Overview
11.12.3 Hester Biosciences Killed-type Poultry Vaccine Product Features and Attributes
11.12.4 Hester Biosciences Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.12.5 Hester Biosciences Recent Developments
11.13 Globion India
11.13.1 Globion India Corporation Information
11.13.2 Globion India Business Overview
11.13.3 Globion India Killed-type Poultry Vaccine Product Features and Attributes
11.13.4 Globion India Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.13.5 Globion India Recent Developments
11.14 Venkys India
11.14.1 Venkys India Corporation Information
11.14.2 Venkys India Business Overview
11.14.3 Venkys India Killed-type Poultry Vaccine Product Features and Attributes
11.14.4 Venkys India Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.14.5 Venkys India Recent Developments
11.15 Bioveta
11.15.1 Bioveta Corporation Information
11.15.2 Bioveta Business Overview
11.15.3 Bioveta Killed-type Poultry Vaccine Product Features and Attributes
11.15.4 Bioveta Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.15.5 Bioveta Recent Developments
11.16 Jilin Zhengye
11.16.1 Jilin Zhengye Corporation Information
11.16.2 Jilin Zhengye Business Overview
11.16.3 Jilin Zhengye Killed-type Poultry Vaccine Product Features and Attributes
11.16.4 Jilin Zhengye Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.16.5 Jilin Zhengye Recent Developments
11.17 Yebio
11.17.1 Yebio Corporation Information
11.17.2 Yebio Business Overview
11.17.3 Yebio Killed-type Poultry Vaccine Product Features and Attributes
11.17.4 Yebio Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.17.5 Yebio Recent Developments
11.18 Sinder
11.18.1 Sinder Corporation Information
11.18.2 Sinder Business Overview
11.18.3 Sinder Killed-type Poultry Vaccine Product Features and Attributes
11.18.4 Sinder Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.18.5 Sinder Recent Developments
11.19 DHN
11.19.1 DHN Corporation Information
11.19.2 DHN Business Overview
11.19.3 DHN Killed-type Poultry Vaccine Product Features and Attributes
11.19.4 DHN Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.19.5 DHN Recent Developments
11.20 JinYu Biotechnology
11.20.1 JinYu Biotechnology Corporation Information
11.20.2 JinYu Biotechnology Business Overview
11.20.3 JinYu Biotechnology Killed-type Poultry Vaccine Product Features and Attributes
11.20.4 JinYu Biotechnology Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.20.5 JinYu Biotechnology Recent Developments
11.21 Guangzhou South China Biological Medicine
11.21.1 Guangzhou South China Biological Medicine Corporation Information
11.21.2 Guangzhou South China Biological Medicine Business Overview
11.21.3 Guangzhou South China Biological Medicine Killed-type Poultry Vaccine Product Features and Attributes
11.21.4 Guangzhou South China Biological Medicine Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.21.5 Guangzhou South China Biological Medicine Recent Developments

12 Killed-type Poultry Vaccine Value Chain and Ecosystem Analysis
12.1 Killed-type Poultry Vaccine Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Killed-type Poultry Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Killed-type Poultry Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Killed-type Poultry Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Killed-type Poultry Vaccine Revenue, 2025
Table 13. Global Killed-type Poultry Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Killed-type Poultry Vaccine Companies Headquarters
Table 15. Global Killed-type Poultry Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 21. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 22. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2021-2026
Table 23. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Killed-type Poultry Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Killed-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 31. North America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Killed-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Killed-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Killed-type Poultry Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Killed-type Poultry Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Killed-type Poultry Vaccine SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Killed-type Poultry Vaccine SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Killed-type Poultry Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Killed-type Poultry Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Killed-type Poultry Vaccine SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. HIPRA Corporation Information
Table 86. HIPRA Description and Major Businesses
Table 87. HIPRA Product Features and Attributes
Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. HIPRA Recent Developments
Table 90. Vaxxinova Corporation Information
Table 91. Vaxxinova Description and Major Businesses
Table 92. Vaxxinova Product Features and Attributes
Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Vaxxinova Recent Developments
Table 95. QYH Biotech Corporation Information
Table 96. QYH Biotech Description and Major Businesses
Table 97. QYH Biotech Product Features and Attributes
Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. QYH Biotech Recent Developments
Table 100. Pulike Corporation Information
Table 101. Pulike Description and Major Businesses
Table 102. Pulike Product Features and Attributes
Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Pulike Recent Developments
Table 105. Harbin Pharmaceutical Group Corporation Information
Table 106. Harbin Pharmaceutical Group Description and Major Businesses
Table 107. Harbin Pharmaceutical Group Product Features and Attributes
Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Harbin Pharmaceutical Group Recent Developments
Table 110. Nisseiken Corporation Information
Table 111. Nisseiken Description and Major Businesses
Table 112. Nisseiken Product Features and Attributes
Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Nisseiken Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Globion India Corporation Information
Table 121. Globion India Description and Major Businesses
Table 122. Globion India Product Features and Attributes
Table 123. Globion India Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Globion India Recent Developments
Table 125. Venkys India Corporation Information
Table 126. Venkys India Description and Major Businesses
Table 127. Venkys India Product Features and Attributes
Table 128. Venkys India Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Venkys India Recent Developments
Table 130. Bioveta Corporation Information
Table 131. Bioveta Description and Major Businesses
Table 132. Bioveta Product Features and Attributes
Table 133. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Bioveta Recent Developments
Table 135. Jilin Zhengye Corporation Information
Table 136. Jilin Zhengye Description and Major Businesses
Table 137. Jilin Zhengye Product Features and Attributes
Table 138. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Jilin Zhengye Recent Developments
Table 140. Yebio Corporation Information
Table 141. Yebio Description and Major Businesses
Table 142. Yebio Product Features and Attributes
Table 143. Yebio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Yebio Recent Developments
Table 145. Sinder Corporation Information
Table 146. Sinder Description and Major Businesses
Table 147. Sinder Product Features and Attributes
Table 148. Sinder Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Sinder Recent Developments
Table 150. DHN Corporation Information
Table 151. DHN Description and Major Businesses
Table 152. DHN Product Features and Attributes
Table 153. DHN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. DHN Recent Developments
Table 155. JinYu Biotechnology Corporation Information
Table 156. JinYu Biotechnology Description and Major Businesses
Table 157. JinYu Biotechnology Product Features and Attributes
Table 158. JinYu Biotechnology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. JinYu Biotechnology Recent Developments
Table 160. Guangzhou South China Biological Medicine Corporation Information
Table 161. Guangzhou South China Biological Medicine Description and Major Businesses
Table 162. Guangzhou South China Biological Medicine Product Features and Attributes
Table 163. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Guangzhou South China Biological Medicine Recent Developments
Table 165. Technologies, Platforms and Infrastructure
Table 166. Distributors List
Table 167. Market Trends and Market Evolution
Table 168. Market Drivers and Opportunities
Table 169. Market Challenges, Risks, and Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Newcastle Disease Vaccines Product Picture
Figure 3. Infectious Bronchitis Vaccines Product Picture
Figure 4. Others Product Picture
Figure 5. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Monovalent Vaccines Product Picture
Figure 7. Multivalent / Combination Vaccines Product Picture
Figure 8. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million)
Figure 9. Preventive Vaccines Product Picture
Figure 10. Prime Vaccines Product Picture
Figure 11. Booster Vaccines Product Picture
Figure 12. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Broiler Farming
Figure 14. Layer Farming
Figure 15. Breeder Farming
Figure 16. Others
Figure 17. Killed-type Poultry Vaccine Report Years Considered
Figure 18. Global Killed-type Poultry Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 19. Global Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 20. Global Killed-type Poultry Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 22. Global Killed-type Poultry Vaccine Revenue-Based Market Share Ranking (2025)
Figure 23. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 24. Newcastle Disease Vaccines Revenue-Based Market Share by Player in 2025
Figure 25. Infectious Bronchitis Vaccines Revenue-Based Market Share by Player in 2025
Figure 26. Others Revenue-Based Market Share by Player in 2025
Figure 27. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 28. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 29. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Function (2021-2032)
Figure 30. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 31. North America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 32. North America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 33. North America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 34. US Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 35. Canada Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 36. Mexico Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 37. Europe Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 38. Europe Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 39. Europe Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 40. Germany Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 41. France Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 42. U.K. Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 43. Italy Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 44. Russia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 45. Asia-Pacific Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 46. Asia-Pacific Top 8 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 47. Asia-Pacific Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 48. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 49. Japan Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 50. South Korea Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 51. Australia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 52. India Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 53. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 54. Vietnam Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Malaysia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 56. Philippines Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Singapore Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Central and South America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 59. Central and South America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 60. Central and South America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 61. Brazil Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 62. Argentina Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 63. Middle East and Africa Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 64. Middle East and Africa Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 65. Middle East and Africa Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 66. GCC Countries Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 67. Israel Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 68. Egypt Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 69. South Africa Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 70. Killed-type Poultry Vaccine Value Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る